Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.43 |
| ▸ | CPN1 | P15169 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755879 | 0.82 | KDM6B (0.54) | MAOBMAOACYP19A1ADRB2CPN1 | |
| SCHEMBL3078044 | 0.79 | MAOB (0.52) | MAOBMAOACYP19A1ADRB2CPN1 | |
| SCHEMBL9929716 | 0.78 | CYP1A2 (0.46) | MAOASIGMAR1 | |
| SCHEMBL21368939 | 0.77 | MAOB (0.50) | MAOBMAOACYP19A1ADRB2CPN1 | |
| SCHEMBL1105056 | 0.77 | MAOB (0.46) | MAOBMAOACYP19A1ADRB2CYP3A4 | |
| SCHEMBL8281166 | 0.76 | ADRB2 (0.52) | MAOBMAOACYP19A1ADRB2CYP3A4 | |
| SCHEMBL7865952 | 0.76 | MAOB (0.48) | MAOBMAOACYP19A1ADRB2CPN1 | |
| SCHEMBL1104874 | 0.74 | PPARG (0.43) | MAOBMAOAADRB2CYP3A4 | |
| SCHEMBL28286282 | 0.72 | MAOA (0.46) | MAOBMAOAADRB2CPN1CPB2 | |
| SCHEMBL385392 | 0.71 | SLC7A5 (0.67) | RECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-9913817-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2018-03-13 | — | — | US | disclosed |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | disclosed |
| US-9682050-B2 | Methods of treating lactose intolerance | NOGRA PHARMA LIMITED (IE) | 2017-06-20 | — | — | US | disclosed |
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2017-03-02 | — | — | US | disclosed |
| US-9561202-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2017-02-07 | — | — | US | disclosed |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150265514-A1 | METHODS OF INHIBITING HAIR GROWTH | NOGRA PHARMA LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | disclosed |
| US-8501806-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2013-08-06 | — | — | US | disclosed |
| US-20130005813-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2013-01-03 | — | — | US | disclosed |
| US-8153841-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-04-10 | — | — | US | disclosed |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | MAOB 250/4885MAOA 359/4885CYP19A1 232/4885 |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | MAOB 2770/4885MAOA 3519/4885CYP19A1 770/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | MAOB 950/4885MAOA 1738/4885CYP19A1 4409/4885 |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | MAOB 250/4885MAOA 359/4885CYP19A1 232/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | MAOB 2825/4885MAOA 3500/4885CYP19A1 2656/4885 |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | APC, GSTK1, GSTA1 | MAOB 1290/4885MAOA 1478/4885CYP19A1 429/4885 |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | EGFR, ERBB3, FGFR3 | MAOB 2770/4885MAOA 3519/4885CYP19A1 770/4885 |
| US-20150265514-A1 | METHODS OF INHIBITING HAIR GROWTH | DCX, HDGF, MKI67 | MAOB 276/4885MAOA 247/4885CYP19A1 629/4885 |
| US-20130005813-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | MAOB 2770/4885MAOA 3519/4885CYP19A1 770/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | MAOB 2825/4885MAOA 3500/4885CYP19A1 2656/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | MAOB 3944/4885MAOA 3577/4885CYP19A1 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.